These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31920347)

  • 1. Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant
    Shi H; Lee JS; Park SY; Ko Y; Eom JS
    Infect Drug Resist; 2019; 12():3925-3934. PubMed ID: 31920347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ineffectiveness of colistin monotherapy in treating carbapenem-resistant Acinetobacter baumannii Pneumonia: A retrospective single-center cohort study.
    Jeon CH; Kim SH; Kim HT; Park KJ; Wi YM
    J Infect Public Health; 2024 May; 17(5):774-779. PubMed ID: 38518683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
    Katip W; Uitrakul S; Oberdorfer P
    Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant
    Katip W; Uitrakul S; Oberdorfer P
    Antibiotics (Basel); 2020 Sep; 9(10):. PubMed ID: 32998187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin Monotherapy versus Colistin plus Sitafloxacin for Therapy of Carbapenem-Resistant
    Sirijatuphat R; Thawornkaew S; Ruangkriengsin D; Thamlikitkul V
    Antibiotics (Basel); 2022 Nov; 11(12):. PubMed ID: 36551364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea.
    Seok H; Choi WS; Lee S; Moon C; Park DW; Song JY; Cheong HJ; Kim J; Kim JY; Park MN; Kim YR; Lee HJ; Kim B; Pai H; Jo YM; Kim JH; Sohn JW
    J Glob Antimicrob Resist; 2021 Mar; 24():429-439. PubMed ID: 33571708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.
    Batirel A; Balkan II; Karabay O; Agalar C; Akalin S; Alici O; Alp E; Altay FA; Altin N; Arslan F; Aslan T; Bekiroglu N; Cesur S; Celik AD; Dogan M; Durdu B; Duygu F; Engin A; Engin DO; Gonen I; Guclu E; Guven T; Hatipoglu CA; Hosoglu S; Karahocagil MK; Kilic AU; Ormen B; Ozdemir D; Ozer S; Oztoprak N; Sezak N; Turhan V; Turker N; Yilmaz H
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1311-22. PubMed ID: 24532009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
    Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
    Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Efficacy and Nephrotoxicity of Colistin Alone versus Colistin Plus Vancomycin in Critically Ill Patients Infected with Carbapenem-Resistant
    Katip W; Oberdorfer P
    Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33530483
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
    Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M;
    Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
    Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
    Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
    Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
    Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective observational study of the impact of plasma colistin levels in patients with carbapenem-resistant Acinetobacter baumannii pneumonia.
    Jeong YJ; Gu N; Kwack WG; Kang Y; Park SY; Yoon YS
    J Glob Antimicrob Resist; 2021 Dec; 27():315-323. PubMed ID: 34775134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant
    Huang C; Chen I; Tang T
    J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant
    Saelim W; Changpradub D; Thunyaharn S; Juntanawiwat P; Nulsopapon P; Santimaleeworagun W
    Infect Chemother; 2021 Mar; 53(1):128-140. PubMed ID: 34409786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-Resistant
    Park JM; Yang KS; Chung YS; Lee KB; Kim JY; Kim SB; Sohn JW; Yoon YK
    Antibiotics (Basel); 2021 Jul; 10(8):. PubMed ID: 34438953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant
    Kim YK; Lee JH; Lee HK; Chung BC; Yu SJ; Lee HY; Park JH; Kim S; Kim HK; Kiem S; Jang HJ
    J Thorac Dis; 2017 Mar; 9(3):555-567. PubMed ID: 28449463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study.
    Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T
    J Infect Public Health; 2023 Aug; 16(8):1249-1255. PubMed ID: 37295057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.
    Kaye KS; Marchaim D; Thamlikitkul V; Carmeli Y; Chiu CH; Daikos G; Dhar S; Durante-Mangoni E; Gikas A; Kotanidou A; Paul M; Roilides E; Rybak M; Samarkos M; Sims M; Tancheva D; Tsiodras S; Kett D; Patel G; Calfee D; Leibovici L; Power L; Munoz-Price S; Stevenson K; Susick L; Latack K; Daniel J; Chiou C; Divine GW; Ghazyaran V; Pogue JM
    NEJM Evid; 2023 Jan; 2(1):. PubMed ID: 37538951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.